Invesco Ltd. Edgewise Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 64,776 shares of EWTX stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,776

Previous 22,244 191.21%

Holding current value

$1.99 Million

Previous $400,000 332.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$15.88 - $29.5 $675,408 - $1.25 Million	42,532 Added 191.21%	64,776 $1.73 Million
Q2 2024 Aug 13, 2024	BUY	$15.08 - $21.23 $16,557 - $23,310	1,098 Added 5.19%	22,244 $400,000
Q1 2024 May 14, 2024	BUY	$9.25 - $19.97 $42,716 - $92,221	4,618 Added 27.94%	21,146 $385,000
Q4 2023 Feb 12, 2024	SELL	$5.51 - $12.1 $35,522 - $78,008	-6,447 Reduced 28.06%	16,528 $180,000
Q3 2023 Nov 13, 2023	BUY	$5.73 - $7.69 $64,473 - $86,527	11,252 Added 95.98%	22,975 $131,000
Q2 2023 Aug 11, 2023	SELL	$5.71 - $10.29 $799 - $1,440	-140 Reduced 1.18%	11,723 $90,000
Q1 2023 May 12, 2023	SELL	$6.66 - $11.33 $6,686 - $11,375	-1,004 Reduced 7.8%	11,863 $79,000
Q4 2022 Feb 13, 2023	BUY	$7.58 - $11.08 $7,345 - $10,736	969 Added 8.14%	12,867 $115,000
Q3 2022 Nov 14, 2022	SELL	$8.08 - $13.58 $517 - $869	-64 Reduced 0.54%	11,898 $117,000
Q2 2022 Aug 15, 2022	SELL	$5.67 - $9.87 $28,038 - $48,807	-4,945 Reduced 29.25%	11,962 $96,000
Q1 2022 May 16, 2022	BUY	$9.1 - $18.97 $3,549 - $7,398	390 Added 2.36%	16,907 $164,000
Q4 2021 Feb 14, 2022	BUY	$14.41 - $22.41 $238,009 - $370,145	16,517 New	16,517 $252,000

Others Institutions Holding EWTX

# of Institutions

191

Shares Held

100M

Call Options Held

2.17M

Put Options Held

410K

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account